Effects of Intraoperative Dexmedetomidine on Postoperative Pain in Highly Nicotine-Dependent Patients After Thoracic Surgery

A Prospective, Randomized, Controlled Trial

Xingzhi Cai, MBBS, Ping Zhang, MS, Sufen Lu, MS, Zongwang Zhang, MD, PhD, Ailan Yu, MD, Donghua Liu, MS, and Shanshan Wu, MBBS

Abstract: To investigate the effects of intraoperative dexmedetomidine on pain in highly nicotine-dependent patients after thoracic surgery.

Highly nicotine-dependent men underwent thoracic surgery and received postoperative patient-controlled intravenous analgesia with sufentanil. In dexmedetomidine group (experimental group, n = 46), dexmedetomidine was given at a loading dose of 1 μg/kg for 10 minutes, followed by continuous infusion at 0.5 μg/kg/h until 30 minutes before the end of surgery. The saline group (control group, n = 48) received the same volume of saline. General anesthesia was administered via a combination of inhalation and intravenous anesthetics. If necessary, patients were administered a loading dose of sufentanil by an anesthetist immediately after surgery (0 hours). Patient-controlled analgesia was started when the patient’s resting numerical rating scale (NRS) score was less than 4. Resting and coughing NRS scores and sufentanil dosage were recorded 0, 1, 4 hours, and every 4 hours until 48 hours after surgery. Dosages of other rescue analgesics were converted to the sufentanil dosage were recorded 0, 1, 4 hours, and every 4 hours until 48 hours after surgery. Dosages of other rescue analgesics were converted to the sufentanil dosage. Surgical data, adverse effects, and degree of satisfaction were obtained.

Cumulative sufentanil dosage, resting NRS, and coughing NRS in the first 24 hours after surgery and heart rate were lower in the experimental group compared with the control group (P < 0.05). No patient experienced sedation or respiratory depression. Frequency of nausea and vomiting and degree of satisfaction were similar in both groups.

Intraoperative dexmedetomidine was associated with reduced resting and coughing NRS scores and a sufentanil-sparing effect during the first 24 hours after thoracic surgery.

(Medicine 95(22):e3814)

Abbreviations: ASA = American Society of Anesthesiologists, BMI = body mass index, DBP = diastolic blood pressure, FTND = Fagerstrom Test of Nicotine Dependence, HR = heart rate, ICU = intensive care unit, IQR = interquartile range, NRS = number rating scale, PCIA = patient-controlled intravenous analgesia, PONV = postoperative nausea and vomiting, SBP = systolic blood pressure.

INTRODUCTION

The goals of postoperative pain management are to relieve pain and reduce the complications of the respiratory and circulatory systems after surgery. In this context, smoking is a predictive factor that, when present, increases the extent of postoperative pain1 and occurrence of perioperative complications.2 Smokers are required to quit smoking just before and during acute postsurgical recovery. Long-term nicotine exposure can alter the structure and function of the pain pathway.3,4 Furthermore, cross-tolerance between opioids and nicotine can occur in smokers.5 Many studies have found that abstaining smokers require larger doses of morphine6,7 and experience higher degrees of postoperative pain compared with nonsmokers.8 Similarly, we previously reported9 that pain severity and sufentanil requirements after surgery increased with increasing nicotine dependence. However, little research has been reported on how to improve analgesia after thoracic surgery for nicotine-dependent patients, especially highly nicotine-dependent patients.

Dexmedetomidine, a new highly selective α2-adrenergic receptor agonist, has sympatholytic, analgesic, and sedative properties, while lacking the side effect of respiratory depression.9 At the supraspinal and spinal levels, dexmedetomidine acts on the α2 adrenoceptors, participating in pain control through modulating nociceptive neurotransmission, inhibiting nociceptive neurons and the release of substance P. Intraoperative dexmedetomidine was shown to improve the effects of postoperative analgesia.9,10 However, whether the same effect is found in highly nicotine-dependent patients has not been determined. Therefore, the aim of this study was to investigate the effects of intraoperative dexmedetomidine on pain management in highly nicotine-dependent patients after thoracic surgery.

METHODS

Participants

Liaocheng People’s Hospital Ethics Committee approval was obtained for this prospective, double-blinded, randomized controlled study, and all participants gave informed consent. The study was registered at chictr.org (ChiCTR-OCH-13004678). All patients who underwent thoracic surgery and received patient-controlled intravenous analgesia (PCIA) between May 2014 and May 2015 at Liaocheng People’s Hospital were eligible for inclusion. Inclusion criteria were classification as American Society of Anesthesiologists I or II, age between 18 and 65 years, male sex, highly nicotine-dependent smoker, and ability to use PCIA and the pain number.
rating scale (NRS, 0 = no pain, 10 = worst possible pain). A patient was classified as a smoker if they had a >1-year history of smoking cigarettes, with a preparative period of smoking cessation of less than 30 days. Patients who were on the nicotine patch or using nicotine nasal spray were not included. No smoking was permitted during PCIA postoperation. The Fagerstrom Test of Nicotine Dependence (FTND) was used to evaluate the extent of nicotine dependence among smokers, with an FTND score ≥ 6 indicating high nicotine dependence. Exclusion criteria were a body mass index greater than 30 kg/m², history of chronic pain and long-term analgesic use, inability to use the PCIA device or use for less than 48 hours, renal or hepatic dysfunction, severe cardiovascular, pulmonary, or psychiatric disease. Heart rate (HR) less than 45 beats per minute (bpm), type I or II atrioventricular block, and allergy to sufentanil or dexmedetomidine. The test drug was stopped and the patient was excluded from the study if the PCIA device malfunctioned, or if the patient underwent secondary surgery, went to the intensive care unit after surgery, or experienced circulatory anomaly after dexmedetomidine use without improvement after conventional treatment.

Randomization and Blinding
An independent anesthesiologist used a computer-generated randomized table to allocate patients to treatment with saline (control group) or dexmedetomidine (experimental group). A nurse in the postanesthesia care unit (PACU) who was not one of the observers for the study prepared injectable solutions containing dexmedetomidine or 0.9% saline. Dexmedetomidine was supplied in 2-mL ampoules (200 µg), which were diluted with 48 mL of saline to a final concentration of 4 µg/mL. For patients in the control group, a 50-mL volume of 0.9% saline solution was prepared.

Anesthesia
Before anesthesia, patients in the experimental group were administered a loading dose of 0.25 mL/kg of 1 µg/kg dexmedetomidine for 10 minutes, followed by continuous infusion at 0.125 mL/kg/h (0.5 µg/kg/h dexmedetomidine) until 30 minutes before the end of surgery. Patients in the control group received the same volume of saline. After anesthesia was induced with intravenous propofol (2 mg/kg), sufentanil (0.3 µg/kg), and cisatracurium (0.2 mg/kg), bronchial intubation was performed. Sevoflurane was inhaled to maintain anesthesia with a minimal alveolar concentration of 1.0 to 1.3 and bispectral index of 40 to 60. Cisatracurium (0.03 g/kg) was given every 1 hour from induction until approximately 1 hour before the end of the operation. Sufentanil (5 µg) was given every 30 minutes from induction until 30 minutes before the end of surgery. Intravenous ketorolac (30 mg) was given 30 minutes before the end of surgery. End-tidal carbon dioxide was maintained at 35 to 40 mm Hg. During surgery, intravenous urapidil (5–10 mg) or ephedrine (6 mg) was given if the mean arterial pressure changed by more than 20% of the baseline value. Atropine (0.2 mg) was administered if the HR fell below 50 bpm.

Postoperative Analgesia Management
After surgery, patients were transferred to the PACU. If necessary, patients were administered the loading dose of sufentanil by an anesthesiologist. PCIA was started through the GemStar pump (Hospira, Lake Forest, IL) when the resting NRS was less than 4. PCIA was maintained until at least 48 hours after surgery. The PCIA device was programmed to deliver a bolus dose of 2 mL of sufentanil (0.8 µg/mL), with a lockout of 5 minutes, no background infusion, and a 4-hour limit of 30 to 40 mL of sufentanil. The goal of PCIA was to maintain the resting NRS score at less than 4. If the NRS score exceeded 4, the patient was given an additional loading dose of 3 µg of sufentanil or the bolus dose was increased from 3 to 4 mL. The 4-hour limit of 40 mL was increased to 50 mL as needed. If the NRS score at rest exceeded 6, then supplemental rescue boluses of intravenous ketorolac (30 mg) or tramadol (100 mg) were used. Patients answered a satisfaction survey after the analgesia service (Question: Are you satisfied with the postoperative analgesia services? Answer: Yes or No).

Outcome Measures
Demographic characteristics were obtained for all patients. Pain assessment included NRS scores at rest and with coughing at arrival to the PACU (0 hours), 1 hour, 4 hours, and every 4 hours thereafter until 48 hours after surgery. Sufentanil dosage was recorded at all time points except 0 hours after surgery. Dosages of other rescue analgesics were converted to the dosage of sufentanil, based on previously described equianalgesic dose ratios (30 mg of ketorolac = 4 µg of sufentanil, 100 mg of tramadol = 10 µg of sufentanil). Surgical data, surgery time, anesthesia time, tracheal extubation time, and dosage of sufentanil during surgery were recorded. Hemodynamic variables, including HR, systolic blood pressure (SBP), and diastolic blood pressure, were observed during surgery. Analgesia-associated adverse effects, such as nausea, vomiting, excessive sedation, and respiratory depression, and degree of satisfaction were obtained.

Statistical Analysis
Sample size was calculated by using PASS 11.0 (NCSS Statistical Software, Kaysville, UT). Data from our previous work gave a mean ± standard deviation (SD) for the cumulative dose of sufentanil of 120 ± 40 µg during the first 24 hours after surgery. Using a power of 80% and 2-sided significance with an α level of 0.05, a sample size of 44 patients was required. Considering a dropout rate of 15%, the final sample size was determined to be 50 patients in each group.

Data were analyzed by using SPSS 17.0 software. Descriptive statistics were used to compare clinical characteristics. Normality of data distributions was assessed with the Kolmogorov–Smirnov test. Levene test was used to determine the homogeneity of variance. Quantitative data are expressed as the mean ± SD for normal distributions or as the median [interquartile range (IQR)] otherwise. Comparisons between groups were made by using the independent-samples t test and Mann–Whitney U test, respectively. Categorical data were described as the number (%) of cases, with the χ² or Fisher Exact Probability test being used to test differences between groups. Pain score data are shown in graphs as the mean and 95% confidence interval, with the repeated-measurement method being used to compare differences between groups. A P value less than 0.05 was considered to be statistically significant.

RESULTS
The flow chart for the patient selection process is shown in Figure 1. Of the 108 recruited patients, 8 patients refused to participate in the study. Therefore, 100 patients were randomly allocated to 2 groups. In experimental group, 4 patients did not complete the study because of PCIA device malfunction (1 patient), HR less than 45 bpm (1 patient), or surgery...
postponement due to patient preference (2 patients). In the control group, 2 patients were excluded because of intensive care unit transfer (1 patient) or PCIA device malfunction (1 patient). Data from the remaining 94 patients were analyzed in this study.

There were no significant differences in baseline characteristics or demographics of patients, such as age, body weight, body mass index, American Society of Anesthesiologists grade, or FTND score (Table 1). Operative time, anesthesia time, awake time, and intraoperative sufentanil dosage did not differ significantly between the groups (Table 2). During the first 24 postoperative hours, the cumulative dosage of sufentanil (Figure 3), NRS at rest, and NRS with coughing (Figure 2) were significantly lower in the experimental compared with the control group; however, these values were not different between the groups beyond 24 postoperative hours (Figures 2 and 3).

Compared with the control group, the HR of the experimental group was significantly lower, but SBP and diastolic blood pressure were not significantly different between the groups (Figure 4). No patient experienced sedation or respiratory depression. Number (%) of patients with postoperative nausea and vomiting (PONV) was 2 (4.35%) in the experimental group and 3 (6.25%) in the control group. No patient expressed dissatisfaction with the postoperative analgesia.

**DISCUSSION**

This report describes the first clinical study showing that intraoperative dexmedetomidine is able to reduce the opioid requirement and pain intensity for highly nicotine-dependent

![FIGURE 1. Flow chart of study selection process. FTND = Fagerstrom Test of Nicotine Dependence, ICU = intensive care unit, PCIA = patient-controlled intravenous analgesia; Experimental group, dexmedetomidine group; Control group, saline group.]

**TABLE 1. Baseline Characteristics and Demographics**

| Characteristic                     | Experimental Group (n = 46) | Control Group (n = 48) | P Value |
|------------------------------------|-----------------------------|------------------------|---------|
| Age, mean ± SD, y                  | 54.6 ± 7.2                  | 55.4 ± 7.3             | 0.590   |
| Weight, mean ± SD, kg              | 64.211.4                    | 63.8 ± 10.6            | 0.494   |
| Height, mean ± SD, cm              | 171.6 ± 8.2                 | 172.8 ± 8.6            | 0.420   |
| BMI, mean ± SD, kg/m²              | 22.8 ± 3.6                  | 22.7 ± 3.4             | 0.900   |
| ASA, I/II                          | 6/40                        | 7/41                   | 0.998   |
| FTND, median [IQR]                 | 7 [6 –8]                    | 7 [6–8]                | 0.898   |
| Education, n (%)                   |                             |                        |         |
| Primary school or less             | 20 (43.5)                   | 20 (41.7)              |         |
| Junior high school                 | 14 (30.4)                   | 15 (31.3)              | 0.997   |
| Senior high school                 | 8 (17.4)                    | 9 (18.8)               |         |
| College or above                   | 4 (8.7)                     | 4 (8.3)                |         |
| Coexisting disease, n (%)          |                             |                        |         |
| Coronary heart disease             | 12 (26.1)                   | 14 (29.2)              | 0.819   |
| Hypertension                       | 14 (30.4)                   | 15 (31.3)              | 0.568   |
| Diabetes                           | 3 (6.5)                     | 3 (6.2)                | 0.622   |
| Chronic bronchitis                 | 6 (13.0)                    | 7 (14.6)               | 0.096   |

Experimental group: dexmedetomidine group; Control group: saline group.

ASA = American Society of Anesthesiologists, BMI = body mass index, FTND = Fagerstrom Test of Nicotine Dependence, IQR = interquartile range.
subjects after thoracic surgery. The findings are consistent with the reported opioid-sparing effect of dexmedetomidine under experimental conditions.9,14

We evaluated the nicotine dependence of smokers according to the FTND, which includes 6 items and has a maximum possible score of 10. Smokers with an FTND score ≥6 were considered to be highly nicotine dependent.11 In the present study, the consumption of sufentanil was greater than in previous reports,15,16 due to the fact that all recruited subjects were highly dependent on nicotine. Our previous retrospective study showed that smokers with high nicotine dependence exhibited higher pain intensity and greater sufentanil usage after thoracic surgery compared with smoker patients with lower nicotine dependence.8 Several mechanisms may contribute to the increase in postoperative pain among smokers. Studies have shown that nicotine-dependent patients have greater pain severity (are hyperalgesic) after surgery and, thus, self-administer sufentanil more frequently to achieve analgesia.17 Another potential reason for the difference in sufentanil consumption is that nicotine-dependent patients might have experienced nicotine abstinence symptoms (e.g., anxiety, depressive mood), prompting greater sufentanil self-administration. Patients may have self-administered higher doses of morphine to relieve their nicotine withdrawal symptoms.

| TABLE 2. Perioperative Data |
|-----------------------------|
| Characteristic              | Experimental Group (n = 46) | Control Group (n = 48) | P   |
| Operative time, mean ± SD, min | 164.72 ± 51.28 | 176.92 ± 61.33 | 0.230 |
| Anesthesia time, mean ± SD, min | 210.56 ± 56.44 | 220.56 ± 62.30 | 0.415 |
| Tracheal extubation time, mean ± SD, min | 10.0 ± 6.6 | 8.6 ± 5.0 | 0.258 |
| Intraoperative sufentanil dosage, mean ± SD, μg | 40.8 ± 4.6 | 42.5 ± 5.6 | 0.099 |
| Type of surgery, n (%) | Thoracoscopic lobectomy | 10 (21.7) | 12 (25) |
| | Open thoracic lobectomy | 6 (13.0) | 4 (8.3) |
| | Single incision esophageal cancer radical prostatectomy | 20 (43.5) | 22 (45.8) | 0.900 |
| | Esophageal cancer radical prostatectomy (cervical, thoracic incision) | 8 (17.4) | 9 (18.8) |
| | Esophageal cancer radical prostatectomy (cervical, thoracic, abdominal incision) | 2 (4.3) | 1 (2.1) |

Dexmedetomidine is an α2-adrenergic receptor agonist that is often used for short-term sedation in patients in intensive care who are on mechanical ventilation, as an adjunct to general anesthesia, and for postoperative pain control.18 The main advantage of this drug is that it does not cause serious respiratory side effects. In addition, it has an opioid-sparing effect. Analgesic, sedative/hypnotic, and anxiolytic properties of dexmedetomidine make this drug potentially useful for painful surgical procedures. In some studies, intravenous dexmedetomidine during surgery was found to have a postoperative opioid-sparing effect or to reduce pain scores.19 These findings are consistent with our research.

Several mechanisms may contribute to dexmedetomidine-mediated reductions in pain intensity and sufentanil dosage in highly nicotine-dependent patients. First, long-term smoking induces nicotine tolerance, which facilitates tolerance to opioid

FIGURE 2. Postoperative numerical rating scale (NRS) scores at rest (A) and with coughing (B). Experimental group: dexmedetomidine group; Control group: saline group. *P < 0.05, **P < 0.01 vs control group. Data are described using the mean and 95% confidence interval.

FIGURE 3. Total dosage of sufentanil throughout the period of postoperative analgesia. Experimental group: dexmedetomidine group; Control group: saline group. *P < 0.05 vs control group.
Dexmedetomidine for Postoperative Analgesia

In summary, this prospective, randomized, controlled trial investigated the effects of intraoperative dexmedetomidine on postoperative analgesia in highly nicotine-dependent patients who underwent thoracic surgery. Intraoperative dexmedetomidine, compared with placebo, reduced NRS scores at rest and with coughing and had a sufentanil-sparing effect during the first 24 hours after thoracic surgery.

REFERENCES

1. Cuff DJ, O’Brien KC, Pupello DR, et al. Evaluation of factors affecting acute postoperative pain levels after arthroscopic rotator cuff repair. Arthroscopy. 2016;32:569–575.

2. Lau D, Chou D, Ziewacz JE, et al. The effects of smoking on perioperative outcomes and pseudarthrosis following anterior cervical corpectomy: clinical article. J Neurosurg Spine. 2014;21:547–558.

3. Nakajima M, Al’Absi M. Nicotine withdrawal and stress-induced changes in pain sensitivity: a cross-sectional investigation between abstinent smokers and nonsmokers. Psychophysiology. 2014;51:1015–1022.

4. Ding Y, Shi W, Xie G, et al. CX3CR1 mediates nicotine withdrawal-induced hyperalgesia via microglial P38 MAPK signaling. Neurochem Res. 2015;40:2252–2261.

5. Zarrindast MR, Khoshayand MR, Shafaghi B. The development of cross-tolerance between morphine and nicotine in mice. Eur Neuropsychopharmacol. 1999;9:227–233.

6. Steinmiller CL, Diederichs C, Roehrs TA, et al. Postsurgical patient-controlled opioid self-administration is greater in hospitalized abstinent smokers than nonsmokers. J Opioid Manag. 2012;8:227–235.

7. Marco AP, Greenwald MK, Higgins MS. A preliminary study of 24-hour post-cesarean patient controlled analgesia: postoperative pain reports and morphine requests/utilization are greater in abstaining smokers than non-smokers. Med Sci Monit. 2005;11:CR255–CR261.

8. Yu A, Cai X, Zhang Z, et al. Effect of nicotine dependence on opioid requirements of patients after thoracic surgery. Acta Anaesthesiol Scand. 2015;59:115–122.

9. Shorrock P, Heaton T, Cochrane N, et al. The effects of dexmedetomidine on postoperative pain. Anaesthesia. 2015;70:372.

10. Cho JS, Kim HI, Lee KY, et al. Effect of intraoperative dexmedetomidine infusion on postoperative bowel movements in patients undergoing laparoscopic gastrectomy: a prospective, randomized, placebo-controlled study. Medicine (Baltimore). 2015;94:e959.
11. Heatherton TF, Kozlowski LT, Frecker RC, et al. The Fagerstrom Test for nicotine dependence: a revision of the Fagerstrom Tolerance Questionnaire. *Br J Addict.* 1991;86:1119–1127.

12. Vallejo R, Barkin RL, Wang VC. Pharmacology of opioids in the treatment of chronic pain syndromes. *Pain Physician.* 2011;14:E343–360.

13. Creekmore FM, Lugo RA, Weiland KJ. Postoperative opiate analgesia requirements of smokers and nonsmokers. *Ann Pharmacother.* 2004;38:949–953.

14. Schnabel A, Meyer-Friesem CH, Reichl SU, et al. Is intraoperative dexmedetomidine a new option for postoperative pain treatment? A meta-analysis of randomized controlled trials. *Pain.* 2013;154:1140–1149.

15. Ramsay MA, Newman KB, Leeper B, et al. Dexmedetomidine infusion for analgesia up to 48 hours after lung surgery performed by lateral thoracotomy. *Proc (Bayl Univ Med Cent).* 2014;27:3–10.

16. Sakakura N, Usami N, Taniguchi T, et al. Assessment of long-term postoperative pain in open thoracotomy patients: pain reduction by the edge closure technique. *Ann Thorac Surg.* 2010;89:1064–1070.

17. Marco AP, Greenwald MK, Higgins MS. A preliminary study of 24-hour post-caesarean patient controlled analgesia: postoperative pain reports and morphine requests/utilization are greater in abstaining smokers than non-smokers. *Med Sci Monit.* 2005;11:CR255–261.

18. Ge DJ, Qi B, Tang G, et al. Intraoperative dexmedetomidine promotes postoperative analgesia in patients after abdominal colectomy: a consort-prospective, randomized, controlled clinical trial. *Medicine (Baltimore).* 2015;94:e1514.

19. Kim HC, Lee YH, Jeon YT, et al. The effect of intraoperative dexmedetomidine on postoperative catheter-related bladder discomfort in patients undergoing transurethral bladder tumour resection: a double-blind randomised study. *Eur J Anaesthesiol.* 2015;32:596–601.

20. Wasiluk IM, Castillo D, Panni JK, et al. Postpartum analgesia with dexmedetomidine in opioid tolerance during pregnancy. *J Clin Anesth.* 2011;23:593–594.

21. Albertson TE, Chenoweth J, Ford J, et al. Is it prime time for alpha2-adrenoceptor agonists in the treatment of withdrawal syndromes. *J Med Toxicol.* 2014;10:369–381.

22. Blaudszun G, Lysakowski C, Elia N, et al. Effect of perioperative systemic alpha2 agonists on postoperative morphine consumption and pain intensity: systematic review and meta-analysis of randomized controlled trials. *Anesthesiology.* 2012;116:1312–1322.

23. Apfel CC, Roewer N. [Risk factors for nausea and vomiting after general anesthesia: fictions and facts]. *Anaesthesist.* 2000;49:629–642.